Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ditaxel
- Development stage
- Unknown
- Lead developer
- Boryung
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Ditaxel is a non-ethanol formulation of docetaxel developed by Boryung Pharmaceutical for the treatment of breast cancer. As a taxane-based chemotherapy, it works by binding to the β-subunit of tubulin, which stabilizes microtubules and prevents their disassembly. This action arrests the cell cycle at the G2/M phase, ultimately leading to apoptosis of the cancer cells. The non-ethanol formulation was specifically designed to mitigate ethanol-related side effects, such as hypersensitivity and symptoms of alcohol intoxication, which are common with traditional docetaxel formulations. It is utilized in both neoadjuvant and adjuvant settings for breast cancer patients.
- Brand names
- Ditaxel
- Other names
- non-ethanol docetaxelBoryung docetaxel
02
Targets
BCL-2 (BCL-2 family)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on Ditaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ditaxel.